The Helene Harris Memorial Trust has become recognized as providing one of the most important international fora for the presentation of research in ovarian cancer. Four biennial meetings have taken place, the most recent of which was held between May 11-14, 1993, in Toronto, Canada. This forum has grown in stature from its inception in 1987 and has brought together interdisciplinary clinical and scientific researchers from around the world who are endeavouring to perform 'cutting edge' studies in the field. The assembled group of presti gious investigators met on this occasion to present…mehr
The Helene Harris Memorial Trust has become recognized as providing one of the most important international fora for the presentation of research in ovarian cancer. Four biennial meetings have taken place, the most recent of which was held between May 11-14, 1993, in Toronto, Canada. This forum has grown in stature from its inception in 1987 and has brought together interdisciplinary clinical and scientific researchers from around the world who are endeavouring to perform 'cutting edge' studies in the field. The assembled group of presti gious investigators met on this occasion to present their data, to exchange ideas, and to arrange collaborations with the goal of developing new means of detection, treatment and cure of ovarian cancer. The incentive for the establishment of the Trust and its international forum was the prema ture loss through ovarian cancer of Helene Harris, the wife of Mr John Harris. Mr Harris and the Trustees looked for a meaningful way to honour the memory of Helene and to advance the noble cause of gaining an increase in the scientific knowledge of the subject. For those of us who spend most of our waking hours assisting patients and their families who are devastated by this disease, the Trust's generosity provides inspiration, hope and the opportunity for their practical application in a unique professional forum.
One Genetics Of Ovarian Cancer.- 1 The genetic epidemiology of ovarian cancer.- 2 Genetic epidemiology of familial ovarian cancer in Utah.- 3 Isolating tumour suppressor genes relevant to ovarian carcinoma - the role of loss of heterozygosity.- 4 The BRCAl gene in sporadic breast and ovarian cancer.- 5 Allele losses on chromosome 17 in ovarian tumours.- 6 Cloning and molecular characterization of monoclonal antibody-defined ovarian tumour antigens.- 7 New insights into the genetics of human ovarian epithelial tumor development.- Two Tumour Biology.- 8 Molecular and biological factors in the pathogenesis of ovarian cancer.- 9 Cytokines and ovarian cancer.- 10 Growth factors and receptors in ovarian cancer.- 11 Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor-?.- 12 TNF, LT AND IL-1 natural inhibitors (soluble receptors and receptor antagonists) in women with ovarian cancer.- 13 Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid.- Three Early Ovarian Cancer and Borderline Tumours.- 14 Update on early ovarian cancer and cancer developing in benign ovarian tumors.- 15 Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer.- 16 Human ovarian surface epithelium: growth patterns and differentiation.- 17 Management of low malignant potential ovarian tumors.- 18 Cellular DNA content: the most important prognostic factor in patients with borderline tumors of the ovary. Can it prevent overtreatment?.- 19 Complementary and coordinate markers for detection of epithelial ovarian cancers.- Four Chemotherapy Radiotherapy and Ethics.- 20 Chemotherapy options in ovarian carcinoma - A dose intensity perspective.- 21 Drug resistance in ovarian cancer andpotential for its reversal.- 22 Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer.- 23 The European-Canadian study of paclitaxel in ovarian cancer. High vs low dose; long vs short infusion.- 24 Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second look laparotomy.- 25 Matrix metalloproteinases and their role in ovarian cancer.- 26 Signal transduction therapy: a new paradigm.- 27 Radiotherapy as salvage or consolidation therapy in advanced epithelial ovarian cancer.- 28 Ethical decision making in the care of seriously ill and dying patients Theory and practice.- Five Immunotherapy and Gene Therapy.- 29 Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF-?/anti-Fas antibody and chemotherapeutic drugs or toxins.- 30 Potential for immunotherapy: PEM as a target antigen.- 31 Ovarian tumour reactive cytotoxic T lymphocytes can recognize peptide determinants on polymorphic epithelial mucins Muc-1.- 32 Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells.- 33 Active specific immunotherapy (ASI). An immunological approach to ovarian cancer treatment.- 34 Antibody targeting of ovarian cancer: recombinant single-chain fragments and the role of internalization.- 35 Carcinoembryonic antigen (CEA) promoter directed tissue specific gene expression in CEA expressing tumour cells.- Six Conclusions and Recommendations.- 36 Conclusions and recommendations.
One Genetics Of Ovarian Cancer.- 1 The genetic epidemiology of ovarian cancer.- 2 Genetic epidemiology of familial ovarian cancer in Utah.- 3 Isolating tumour suppressor genes relevant to ovarian carcinoma - the role of loss of heterozygosity.- 4 The BRCAl gene in sporadic breast and ovarian cancer.- 5 Allele losses on chromosome 17 in ovarian tumours.- 6 Cloning and molecular characterization of monoclonal antibody-defined ovarian tumour antigens.- 7 New insights into the genetics of human ovarian epithelial tumor development.- Two Tumour Biology.- 8 Molecular and biological factors in the pathogenesis of ovarian cancer.- 9 Cytokines and ovarian cancer.- 10 Growth factors and receptors in ovarian cancer.- 11 Cell growth regulation in ovarian cancer: tyrosine kinases, tyrosine phosphatases and tumour necrosis factor-?.- 12 TNF, LT AND IL-1 natural inhibitors (soluble receptors and receptor antagonists) in women with ovarian cancer.- 13 Activation of human ovarian cancer cells: role of lipid factors in ascitic fluid.- Three Early Ovarian Cancer and Borderline Tumours.- 14 Update on early ovarian cancer and cancer developing in benign ovarian tumors.- 15 Spontaneous transformation of the ovarian surface epithelium and the biology of ovarian cancer.- 16 Human ovarian surface epithelium: growth patterns and differentiation.- 17 Management of low malignant potential ovarian tumors.- 18 Cellular DNA content: the most important prognostic factor in patients with borderline tumors of the ovary. Can it prevent overtreatment?.- 19 Complementary and coordinate markers for detection of epithelial ovarian cancers.- Four Chemotherapy Radiotherapy and Ethics.- 20 Chemotherapy options in ovarian carcinoma - A dose intensity perspective.- 21 Drug resistance in ovarian cancer andpotential for its reversal.- 22 Taxol and Taxotere: new drugs of interest in the treatment of advanced ovarian cancer.- 23 The European-Canadian study of paclitaxel in ovarian cancer. High vs low dose; long vs short infusion.- 24 Intraperitoneal recombinant interferon-gamma in ovarian cancer patients with residual disease at second look laparotomy.- 25 Matrix metalloproteinases and their role in ovarian cancer.- 26 Signal transduction therapy: a new paradigm.- 27 Radiotherapy as salvage or consolidation therapy in advanced epithelial ovarian cancer.- 28 Ethical decision making in the care of seriously ill and dying patients Theory and practice.- Five Immunotherapy and Gene Therapy.- 29 Overcoming drug resistance of ovarian carcinoma cell lines by treatment with combination of TNF-?/anti-Fas antibody and chemotherapeutic drugs or toxins.- 30 Potential for immunotherapy: PEM as a target antigen.- 31 Ovarian tumour reactive cytotoxic T lymphocytes can recognize peptide determinants on polymorphic epithelial mucins Muc-1.- 32 Use of bifunctional monoclonal antibodies for retargeting human lymphocytes against ovarian carcinoma cells.- 33 Active specific immunotherapy (ASI). An immunological approach to ovarian cancer treatment.- 34 Antibody targeting of ovarian cancer: recombinant single-chain fragments and the role of internalization.- 35 Carcinoembryonic antigen (CEA) promoter directed tissue specific gene expression in CEA expressing tumour cells.- Six Conclusions and Recommendations.- 36 Conclusions and recommendations.
Es gelten unsere Allgemeinen Geschäftsbedingungen: www.buecher.de/agb
Impressum
www.buecher.de ist ein Internetauftritt der buecher.de internetstores GmbH
Geschäftsführung: Monica Sawhney | Roland Kölbl | Günter Hilger
Sitz der Gesellschaft: Batheyer Straße 115 - 117, 58099 Hagen
Postanschrift: Bürgermeister-Wegele-Str. 12, 86167 Augsburg
Amtsgericht Hagen HRB 13257
Steuernummer: 321/5800/1497
USt-IdNr: DE450055826
